bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-β and dihydrotestosterone in prostate cancer cells

Prostate

Volumn 53, Issue 2, 2002, Pages 133-142

  Bruckheimer, Elizabeth M ^a   Kyprianou, Natasha ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Androgen regulation; Androgens; Apoptosis; bcl 2; Caspases; Prostate cancer; TGF

Indexed keywords

ANDROSTANOLONE; HYGROMYCIN; INTERLEUKIN 1BETA CONVERTING ENZYME; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ENGINEERING; GENETIC TRANSFECTION; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HUMAN CELL; MALE; MOLECULAR CLONING; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 1; DIHYDROTESTOSTERONE; GENES, BCL-2; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0036787491     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10143     Document Type: Article

References (56)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 2000;50:7-33.
2. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Bueschen AJ, Lowe BA. Bilateral orchitectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;333:1036-1042.
3. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-3753.
4. Westin P, Stattin P, Damber J-E, Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995;146:1368-1375.
5. Bruckheimer EM, Kyprianou N. Apoptosis in prostate carcinogenesis: a growth regulator and a therapeutic target. Cell Tissue Res 2000;301:152-162.
6. Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122: 552-562.
7. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000; 42:150-160.
8. Kyprianou N, Isaacs JT. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989;3:1515-1522.
9. Wikstrom P, Westin P, Stattin P, Damber J-E, Bergh A. Early castration-induced upregulation of transforming growth factor β1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer specimens. Prostate 1999;38:268-277.
10. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28:392-405.
11. Wrana J, Attisano L, Wiesert R, Ventura F, Massague J. Controlling TGF-beta signaling. Genes Dev 2000;14:627-644.
12. Guo Y, Kyprianou N. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-β1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ 1998;9:185-193.
13. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato M, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996;2:1255-1261.
14. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl 1992;16:54-61.
15. Guo Y, Jacobs SC, Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF- β1) type I and type II receptors in human prostate cancer. Int J Cancer 1997;71:573-579.
16. Guo Y, Kyprianou N. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 1999;59:1366-1371.
17. Bruckheimer EM, Cho SH, Sarkiss M, Herrmann JL, McDonnell TJ. The Bcl-2 gene family and apoptosis. Adv Biochem Eng Biotechnol 1998;62:75-105.
18. Perlman H, Zhang X, Chen MW, Walsh K, Buttyan R. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ 1999;6:48-54.
19. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944.
20. Tu H, Jacobs SC, Kyprianou N. Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-β and bcl-2 expression. Int J Cancer 1997;69:357-363.
21. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
22. Shabaik AS, Krajewski S, Burgan A, Reed JC. bcl-2 protooncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J Urol Pathol 1995;3:17-27.
23. Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.
24. Berchem GI, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelman EP. Androgens induce resistance to bcl-2 mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995;55:735-738.
25. Westin P, Lo P, Marin CM, Fernandez A, Sarkiss M, Tu S-M, Brisbay SM, von Eschenbach AC, McDonnell TJ. bcl-2 expression confers androgen independence in androgen sensitive prostatic carcinoma. Int J Oncol 1997;10:113-118.
26. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;236:1-16.
27. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 1999;274:20049-20052.
28. Zou H, Li Y, Liu X, Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-11556.
29. Bossy-Wetzel E, Green DR. Caspases induce cytochrome c release from mitochondria by activating cytosolic factors. J Biol Chem 1999;274:17484-17490.
30. Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 1998;58:76-83.
31. Bowen C, Voeller HJ, Kikly K, Gelmann EP. Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells. Cell Death Differ 1999;6:394-401.
32. Marcelli M, Cunningham GR, Walkup M, He Z, Sturgis L, Kagan C, Mannucci R, Nicoletti I, Teng B, Denner L. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res 1999;59:382-390.
33. Srikanth S, Kraft AS. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res 1998;58:834-839.
34. Chen R-H, Chang T-Y. Involvement of caspase family proteases in transforming growth factor-beta-induced apoptosis. Cell Growth Differ 1997;8:821-827.
35. Brown TL, Patil S, Basnett RK, Howe PH. Caspase inhibitor BD-fmk distinguishes transforming growth factor beta-induced apoptosis from growth inhibition. Cell Growth Dev 1998;9:869- 875.
36. Brustugun OT, Fladmark KE, Doskeland SO, Orrenius S, Zhivotovsky B. Apoptosis induced by microinjection of cytochrome c is caspase-dependent and is inhibited by Bcl-2. Cell Death Differ 1998;5:660-668.
37. Chipuk JE, Bhat M, Hsing AY, Ma J, Danielpour D. Bcl-xL blocks TGF-β induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells. J Biol Chem 2001;276:26614-26621.
38. Bruckheimer EM, Kyprianou N. Dihydrotestosterone enhances transforming growth factor-induced apoptosis in hormone- sensitive prostate cancer cells. Endocrinology 2001;142:2419-2426.
39. Bruckheimer EM, Cho S, Brisbay S, Johnson DJ, Gingrich JR, Greenberg N, McDonnell TJ. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo. Oncogene 2000;19:2404-2412.
40. L downregulation. Exp Cell Res 1998;242:244- 254.
41. Herrera B, Alvarez AM, Sanchez A, Ferbandez M, Roncero C, Benito M, Fabrega I. Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor in fetal hepatocytes. FASEB 2001;15:741-751.
42. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-Non- Hodgkin's Lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in downregulation of bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61: 5137-5144.
43. Francis JM, Heyworth CM, Spoonce E, Pierce A, Dexter TM, Whetton AD. Transforming growth factor-β induces apoptosis independently of p53 and selectively reduces expression of bcl-2 in multipotent hematopoietic cells. J Biol Chem 2000;275:39137- 39145.
44. Tobin SW, Brown MK, Douville K, Payne DC, Eastman A, Arrick BA. Inhibition of transforming growth factor beta signaling in MCF-7 cells results in resistance to tumor necrosis factor alpha: a role for bcl-2. Cell Growth Differ 2001;12:109-117.
45. Tsukada T, Eguchi K, Migita K, Kawabe Y, Kawakami A, Matsuoka N, Takashima H, Mizzokami A, Nagataki S. Transforming growth factor-β induces apoptotic cell death in cultured human umbilical vein endothelial cells with down-regulated expression of bcl-2. Biochem Biophys Res Commun 1995;210:1076-1080.
46. Rokhlin OW, Guseva N, Tagiyev A, Knidson CM, Cohen M. bcl- 2 oncoprotein protects the human prostatic carcinoma cell line PC-3 from TRAIL-mediated apoptosis. Oncogene 2001;20: 2836-2843.
47. Weller M, Constam DB, Malipiero U, Fontana A. Transforming growth factor-β induces apoptosis of murine T-cell clones without downregulating bcl-2 mRNA expression. Eur J Immunol 1994;24:1293-1300.
48. Totth A, Sebestyen A, Barna G, Nagy K, Gondor A, Bocsi J, Mihalik R, Petak I, Houghton J, Kopper L. TGF-β induces caspase-dependent but death-receptor independent apoptosis in lymphoid cells. Anticancer Res 2001;21:1207-1212.
49. Bruckheimer EM, Brisbay SM, Gingrich JR, Greenberg NM, Weigel N, McDonnell TJ. The contribution of bcl-2 to prostate cancer progression in in vitro and in vivo models. Proc Am Assoc Cancer Res 1999;40:526.
50. Lapointe J, Fournier A, Richard V, Labrie C. Androgen down- regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology 1999;140:416-420.
51. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst 2000;92:1388-1402.
52. Fernandez A, Udagawa T, Schwesinger C, Beecken W-D, Achilles-Gerte E, McDonnell TJ, D'Amato RJ. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001;93:208-213.
53. Kimura K, Markowski M, Bowen C, Gelman EP. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res 2001;61:5611-5618.
54. de Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F. Characteristics of biphasic action of androgens and the of the potent anti-proliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 1991;51:5165-5170.
55. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999;59:4161-4164.
56. Gormley GJ, Brawley O, Thompson I. The potential application of finasteride for chemoprevention of prostate cancer. Ann. N Y Acad. Sci 1995;768:163-169.